Denmark, 12 June 2023 Novo Nordisk has announced to make an investment of USD 2.3 billion investment to enhance its Active Pharmaceutics production, the main biologically active components of medicines manufacturing at its location in Hillerod, Denmark. The investment was made to meet the demand for its chronic kidney drugs. At its location in Hillerod, Novo is building a new 700,000-square-foot, multi-product factory that will begin producing APIs by 2029. The production of semaglutide is not included in this expansion at Hillerd facility. The company also intends to employ about 340 people at the production facility. The incorporation of cutting-edge technology, and the company intends to distribute goods in an efficient and environmentally sustainable way. The investment in Hillerd, Denmark will increase Novo Nordisk’s production capacity, increase its ability to meet future market demands, and be a crucial enabler for Novo Nordisk to build its future clinical late-phase product portfolio.
The new facility, which would be roughly of 700,000 m2, and would build as a multi-product facility with the most flexibility possible to accommodate new processes and display state-of-the-art technology and working conditions. The facility will concentrate on providing the best care possible to patients around the world in an effective and environmentally friendly manner as a facility that is future-proof and cost-effective. This will be accomplished by creating process flows that are both compact and optimum, which significantly reduce consumption water and energy. Additionally, these investments ensure that its late-phase pipeline continues to advance and that crucial medications are delivered to patients around the world for treatment.
About Novo Nordisk
Novo Nordisk is a global pharmaceutical company specializing in the development and production of medicines and treatments for diabetes, obesity, and other serious chronic conditions. The company is founded in Denmark in 1923, and headquartered are located in Bagsværd, Denmark. Novo Nordisk has grown to become one of the leading players in the healthcare industry, with a strong focus on research, innovation, and patient care. Novo Nordisk has a global presence, with operations in over 80 countries and more than 57,100 employees worldwide and markets its products in around 170 countries.
Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation
June 8, 2023, Sonoma Pharmaceuticals, Inc., a leader in the global healthcare industry that creates and manufactures stabilised hypochlorous acid (HOCl) products based on the patented Microcyn® technology for a variety of uses, including wound care, dermatology, and care for the eyes, mouth, and nose, announced launch of intraoperative pulse lavage irrigation treatment that can replace frequently used IV bags in a range of surgical procedures.
Sonoma developed this new use of their wound care technology to fill a market need for a non-toxic irrigation solution that can prevent infection and hasten recovery. The intraoperative pulse lavage container can be used in conjunction with a flush gun, also referred to as a pulse lavage irrigation device, during the abdominal, laparoscopic, orthopaedic, and periprosthetic procedures. With this product, safe and effective Microcyn® Technology takes the place of harsh rinse solutions and non-antimicrobial saline. Microcyn® Technology is crucial for preventing infection and speeding up wound healing because it is non-toxic, regenerative, and helps to eliminate germs. In addition, Sonoma’s pulse lavage container is more affordable than IV bags, which are the current standard of care.
The company developed the intraoperative pulse lavage irrigation procedure in close cooperation with the medical industry and Sonoma’s current distribution partners in Europe. Sonoma believes that this new application would be well appreciated. As of right now, Sonoma is taking pre-orders for the pulse lavage irrigation treatment product, which will go on sale in Europe in September 2023. Sonoma intends for a commercial debut in the US in 2024.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets innovative solutions for dermatological conditions and other healthcare markets. Sonoma Pharmaceuticals was founded in 1999 and is headquartered in Petaluma, California, United States. The company is focused on developing and commercializing products that address unmet medical needs and improve patient outcomes. Sonoma Pharmaceuticals has a global presence and operates in multiple international markets. They have established partnerships and distribution channels in various countries to make their products accessible to patients worldwide. The company’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners.